Iatrogenic Cushing syndrome following lumbar medial branch block in a patient with HIV on ritonavir and darunavir

Research output: Contribution to journalArticlepeer-review

Abstract

We present a case report of a 62-year old female with HIV and chronic facetogenic back pain who underwent bilateral L3-L4 and L4-L5 medial branch nerve blocks using triamcinolone acetonide 80 mg. 2 weeks later she presented to the emergency department with acute anxiety/depression and was discharged with psychiatric follow-up. 2 weeks after this she presented to the outpatient HIV clinic with persistent uncontrolled depression alongside classic cushingoid features (e.g., buffalo hump, moon facies). She was diagnosed with iatrogenic Cushing syndrome caused by a drug-drug interaction between triamcinolone and ritonavir, a protease inhibitor and a CYP3A4 enzyme inhibitor. While the literature describes the interaction of ritonavir with intra-articular/intranasal/epidural triamcinolone, this is the first documented occurrence following a nerve block procedure. Symptoms resolved within 6 months alongside discontinuation of protease inhibitor therapy.
Original languageEnglish
Pages (from-to)381-387
Number of pages7
JournalPain Management
Volume11
Issue number4
DOIs
StatePublished - May 2021

Bibliographical note

Publisher Copyright:
© 2021.

Funding

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

ASJC Scopus Subject Areas

  • Anesthesiology and Pain Medicine

Keywords

  • corticosteroids
  • cushing syndrome
  • HIV
  • pain management
  • triamcinolone

Disciplines

  • Anesthesiology

Fingerprint

Dive into the research topics of 'Iatrogenic Cushing syndrome following lumbar medial branch block in a patient with HIV on ritonavir and darunavir'. Together they form a unique fingerprint.

Cite this